Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.
Axion BioSystems’ Letter of Intent for its Human iPSC-Cardiomyocyte MEA Assay for Prediction of Clinical Cardiovascular ...
A groundbreaking study shatters the myth of permanent cardiac damage, revealing that the heart can naturally trigger cell ...
Japanese government experts endorsed on Thursday ground-breaking projects to manufacture regenerative medicine products to ...
MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric ...
Japan Approves Worlds First iPS Therapies for Parkinsons, Heart Failure Conditional approval granted for Sumitomo Pharmas ...
The innermost layer of blood vessels is formed by endothelial cells, which in turn play a role in the development of diseases of the cardiovascular system. Human endothelial cells are therefore ...
KENNEDY SPACE CENTER (FL), March 28, 2025 – Heart disease remains the leading cause of death in the United States, accounting for one in five deaths. The inability of damaged heart muscle tissue to ...
Scientists have created a three-dimensional "heart-on-a-chip" (HOC) that could provide a breakthrough in the fight against the world's leading cause of death, cardiovascular disease. One major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results